Literature DB >> 4640811

Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.

A J Kastin, A Barbeau.   

Abstract

The present study, carried out in 16 parkinsonian patients, indicates that L-prolyl-L-leucyl-glycine amide possesses some antiparkinsonian activity and that, if used with levodopa, it can reduce some of the drug-induced dyskinesias. These preliminary observations should be submitted to a controlled trial in a large number of patients before therapeutic applications are claimed.

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4640811      PMCID： PMC1941054     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN： 0008-4409            Impact factor:   8.262


  12 in total

1.  Isolation and structure of hypothalamic MSH release-inhibition hormone.

Authors:  R M Nair; A J Kastin; A V Schally
Journal:  Biochem Biophys Res Commun       Date:  1971-06-18       Impact factor: 3.575

2.  Long-term side-effects of levodopa.

Authors:  A Barbeau
Journal:  Lancet       Date:  1971-02-20       Impact factor: 79.321

3.  MSH activity in plasma and pituitaries of rats after various treatments.

Authors:  A J Kastin; A V Schally; S Viosca; M C Miller
Journal:  Endocrinology       Date:  1969-01       Impact factor: 4.736

4.  Inhibition of MSH release in frogs by direct application of L-proplyl-L-leucylglycinamide to the pituitary.

Authors:  A J Kastin; A V Schally; S Viosca
Journal:  Proc Soc Exp Biol Med       Date:  1971-09

5.  Adverse clinical side effects of levodopa therapy.

Authors:  A Barbeau; H Mars; L Gillo-Joffroy
Journal:  Contemp Neurol Ser       Date:  1971

6.  DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).

Authors:  N P Plotnikoff; A J Kastin; M S Anderson; A V Schally
Journal:  Life Sci I       Date:  1971-11-15

7.  [Method of measurement of akinesia].

Authors:  M Joubert; A Barbeau
Journal:  Union Med Can       Date:  1966-05

8.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

9.  Oxotremorine antagonism by a hypothalamic hormone, melanocyte-stimulating hormone release-inhibiting factor (MIF).

Authors:  N P Plotnikoff; A J Kastin; M S Anderson; A V Schally
Journal:  Proc Soc Exp Biol Med       Date:  1972-07

10.  Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors:  F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391
View more
  13 in total

1.  On the optimal dosage of Pro-Leu-Gly-NH2 (MIF) in neuropharmacological tests and clinical use.

Authors:  S Björkman; H Sievertsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-06       Impact factor: 3.000

Review 2.  Concepts for biologically active peptides.

Authors:  Abba J Kastin; Weihong Pan
Journal:  Curr Pharm Des       Date:  2010-10       Impact factor: 3.116

3.  Failure of MIF-I to affect behavioral responses in patients with Parkinson's diseases under L-dopa therapy.

Authors:  T Caraceni; E A Parati; F Girotti; I Celano; C Frigerio; D Cocchi; E E Müller
Journal:  Psychopharmacology (Berl)       Date:  1979-06-21       Impact factor: 4.530

4.  Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease.

Authors:  A Barbeau; M Roy; A J Kastin
Journal:  Can Med Assoc J       Date:  1976-01-24       Impact factor: 8.262

5.  Long-term therapy of Parkinson's disease with amantadine, alone and combined with levodopa.

Authors:  L R Zeldowicz; J Hubermann
Journal:  Can Med Assoc J       Date:  1973-10-06       Impact factor: 8.262

6.  Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease.

Authors:  J R Bianchine; L Sunyapridakul
Journal:  Drugs       Date:  1973       Impact factor: 9.546

7.  Parkinson's disease, melanoma, and levodopa.

Authors:  J Fermaglich; P Delaney
Journal:  J Neurol       Date:  1977-06-13       Impact factor: 4.849

8.  The pigmentary system of planaria. II. Physiology and functional morphology.

Authors:  G Palladini; L Medolago-Albani; V Margotta; A Conforti; A Carolei
Journal:  Cell Tissue Res       Date:  1979-06-27       Impact factor: 5.249

9.  Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys.

Authors:  T J Crowley; M Hydinger
Journal:  Psychopharmacology (Berl)       Date:  1977-07-18       Impact factor: 4.530

Review 10.  The hypothalamus in Parkinson disease.

Authors:  R Sandyk; R P Iacono; C R Bamford
Journal:  Ital J Neurol Sci       Date:  1987-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.